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Manipulating RyR2 Ca2D Signalling in Cardiomyocyte Networks using
Morpholino Oligonucleotides
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Magdalena Lipka1, Alice N. Mitchell1, Nicole C. Silvester1,
Branko V. Latinkic2, Christopher H. George1.
1Wales Heart Research Institute & Institute of Molecular and Experimental
Medicine, Cardiff University, Cardiff, United Kingdom, 2School of
Biosciences, Cardiff University, Cardiff, United Kingdom.
Pharmacologic and gene-based approaches to normalise excitation-contraction
coupling (ECC) in heart disease often provoke compensatory adaptations. We
proposed that such (mal)adaptation re-configures homeostatic Ca2þ signalling
network to a new state that may directly contribute to disease pathogenesis
(George et al., AJP 2012). We sought to investigate approaches that could mod-
ulate disease-linked Ca2þ release abnormalities without perturbing homeostatic
Ca2þ signalling. In this proof-of-concept study we investigated the utility of
a morpholino oligonucleotide targeted to exon1 of RyR2 (rMO) to modify
Ca2þ release in HL-1 cardiomyocyte networks. Imaging of fluorescein-
labelled MOs revealed a homogeneous time- and concentration-dependent ac-
cumulation of MO in the cytoplasm of >80% HL-1 cardiomyocytes. The effi-
cacy of rMO-mediated protein knock-down was assessed using a construct
encoding RyR2 exon 1 (bases 1-25) fused to the N-terminus of eGFP. The
use of a control MO (cMO), that has no homology to known mammalian
RNAs, and the expression of eGFP minus the RyR2 exon 1 confirmed the spec-
ificity of rMO effects. Incubation of HL-1 syncytia with rMO (24-72h, 1-10uM)
did not alter RyR2 mRNA abundance and spontaneous Ca2þ oscillations and
intercellular synchronisation of Ca2þ release remained unchanged. Despite
near-identical basal Ca2þ oscillations in rMO- and cMO-treated HL-1 popula-
tions, caffeine-evoked Ca2þ transients were modulated by rMO in a concentra-
tion- and time-dependent manner. We expanded this study to determine the
effects of rMO in human ES-derived cardiomyocytes over a longer time period
(21 days). Our data support the development of MO-based methods to modulate
discrete aspects of Ca2þ signalling in cardiac disease.
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Cardiac Hypertrophy Associated with Impaired Regulation of Type2
Ryanodine Receptor Calcium Channel by Calmodulin and S100A1
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1Medical University of South Carolina, Charleston, SC, USA, 2University of
North Carolina, Chapel Hill, NC, USA.
The cardiac ryanodine receptor ion channel (RyR2) is inhibited in vitro by cal-
modulin (CaM). Simultaneous substitution of three amino acid residues in the
CaM binding domain (W3587A/L3591D/F3603A, RyR2ADA) leads to loss of
CaM inhibition at submicromolar (diastolic) and micromolar (systolic) Ca2þ
concentrations in vitro and cardiac hypertrophy and heart failure in mice. To
address whether elimination of CaM inhibition at diastolic or systolic Ca2þ
causes cardiac hypertrophy, a second mutant mouse was prepared with a single
amino acid substitution (L3591D, RyR2D) in the CaM binding domain. In sin-
gle channel measurements, RyR2D lost CaM inhibition at diastolic but not sys-
tolic Ca2þ, and lost inhibition by the small Ca2þ binding protein S100A1 at
both diastolic and systolic Ca2þ. In contrast to Ryr2ADA/ADA mice, Ryr2D/D
mice had a normal lifespan and cardiac contractility. In 6-month old Ryr2D/D
mice, heart-to-body weight ratio increased by 8% with a two-fold upregulation
of atrial natriuretic peptide mRNA levels and a 40% decrease in RyR2 content.
Differences between mutant and wild-type mice were more prominent in mice
subjected to 4 weeks pressure overload using transverse aortic constriction. The
results contrast those of Ryr2ADA/ADA mice that have an impaired cardiac con-
tractile performance and die at ~2 weeks after birth, and suggest that CaM in-
hibition of RyR2 at systolic Ca2þ is important for maintaining normal cardiac
function. Supported by NIH, AHA and NSF.
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The CPVT-Associated RyR2 Mutation G230C reduces the Threshold for
Store Overload-Induced Ca Release (SOICR)
Yingjie Liu, Florian Hiess, Xixi Tian, Ruiwu Wang, S.R. Wayne Chen.
Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-
threatening arrhythmia. Many congenital mutations in both the cardiac ryano-
dine receptor (RyR2) and calsequestrin (CASQ2) are known to be responsible
for this disorder. It is now well established that CPVT is caused by delayed
afterdepolarizations (DADs)-induced triggered activities, and that DADs are
caused by spontaneous sarcoplasmic reticulum (SR) Ca release during Ca
overload, a process also known as store overload induced Ca release (SOICR).
A large body of evidence indicates that CPVT-causing RyR2 and CASQ2mutations enhance the propensity for SOICR and DADs by increasing the re-
sponse of RyR2 to SR luminal Ca. Recently, Marks and colleagues reported
that a CPVT RyR2 mutation G230C increases the cytosolic Ca sensitivity
(only after PKA phosphorylation) of single RyR2 channels in lipid bilayers,
but has no effect on the luminal Ca sensitivity of the channel. These observa-
tions have led to the conclusion that SOICR is not involved in the disease
mechanism of the RyR2-G230C mutation. However, the cellular impact of
this mutation on SOICR has yet to be determined. To this end, we generated
stable, inducible HEK293 cell lines expressing RyR2-WT and the RyR2-
G230C mutant. We induced SOICR in these cells by elevating extracellular
Ca, and found that the RyR2-G230C mutation markedly enhances the propen-
sity for SOICR. Further, we employed single cell luminal Ca imaging to mon-
itor the luminal Ca dynamics in RyR2-WT- and G230C-expressing cells during
store Ca overload. We found that the G230C mutation significantly reduces the
luminal Ca level at which spontaneous Ca release occurs (i.e. the SOICR
threshold). Therefore, these results and those of previous studies demonstrate
that reduced SOICR threshold is a common defect of CPVT-associated
RyR2 mutations.
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The L433P Arrhythmia-Linked Mutation Disrupts Amino-Terminus
Oligomerisation of the Human Cardiac Ryanodine Receptor
Monika K. Seidel, F. Anthony Lai, Spyros Zissimopoulos.
Cardiff University School of Medicine, Cardiff, United Kingdom.
The type 2 ryanodine receptor (RyR2) mediates calcium release from the
sarcoplasmic reticulum of cardiomyocytes. RyR2 mutations found in three
clusters including the amino-terminus are associated with arrhythmogenic car-
diac disease. Arrhythmia-linked mutations are proposed to disrupt interactions
between discrete functional domains within the RyR2 tetramer, resulting in
abnormal channel gating. Recently, we presented evidence that the RyR2
N-terminus self-associates into a tetrameric form, which stabilises the closed
channel conformation.
Here, we report that the arrhythmia-associated L433P mutation affects oligo-
merisation of the RyR2 N-terminus. Tetramerisation ability was tested by
chemical cross-linking experiments of an RyR2 N-terminal fragment (residues
1-906) containing L433P, expressed in HEK293 cells. The mutant fragment
displayed reduced ability for tetramerisation versus wild-type. Two additional
techniques, the yeast two-hybrid system and co-immunoprecipitation assays,
further indicated that the mutant fragment displays reduced self-interaction
and reduced binding to wild-type N-terminus. Notably, dantrolene, a drug
used to treat the clinical symptoms of malignant hyperthermia and whose
target-binding site lies within the RyR N-terminus, was able to partially restore
the tetramer in the L433P mutant.
The effect of the L433P mutation was also investigated in the context of the
full-length channel. We performed sucrose density gradient centrifugation of
CHAPS-solubilised RyR2 to assess the relative stability of tetrameric func-
tional channels. We found that wild-type RyR2 remains a tetramer consistent
with an intact functional channel, whereas a substantial proportion of RyR2/
L433P channels is dissociated into monomers.
Our findings suggest that disruption of inter-subunit interactions within the
N-terminus of mutant RyR2 might contribute to the mechanism by which
some of the arrhythmia-associated mutations result in RyR2 channel
dysfunction.
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ATP and Caffeine Binding to the Human RyR2 Central Domain Encom-
passing a CPVT Mutation Cluster
Lynda Blayney, Michail Nomikos, Leon D’Cruz, Ewan McDonald,
Julia Griffiths, F. Anthony Lai.
Cardiff University, Cardiff, United Kingdom.
The sarcoplasmic reticulum (SR) of cardiomyocytes contains the cardiac
ryanodine receptor (RyR2) - a calcium release channel that plays a pivotal
role in mediating the SR calcium release essential for cardiac excitation-
contraction coupling. Discrete clusters of point mutations, that may comprise
important regulatory regions within RyR2, have been associated with catechol-
aminergic polymorphic ventricular tachycardia (CPVT). In response to a phys-
iological trigger, RyR2 bearing CPVT mutations are believed to cause diastolic
calcium leak, which can result in a fatal arrhythmia. A RyR2 central domain,
which encompasses both a CPVT-associated region and a predicted ATP
binding motif, has been expressed as a soluble recombinant protein. The
wild-type protein was compared with three constructs each containing a differ-
ent CPVT mutation (P2328S, F2331S and N2368I). ATP is a physiological
activator of RyR2 activity and caffeine has a similar effect. Fluorescence
spectroscopy was used to record changes in the intrinsic fluorescence of the
single tryptophan residue present within the expressed domain, and we found
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We observed a similar binding affinity of the expressed RyR2 central domain
for both compounds, with an EC50 ~100mM. The presence of the individual
mutations made no apparent difference to the EC50. However, there was an in-
creased initial fluorescence value observed for each of the mutant constructs
compared to WT. Analysis of the central domain sequence revealed homology
with conserved motifs typical of P-loop kinases. Interestingly, many of the
CPVT mutations present in this region are coincident with sites corresponding
to the Walker A, Walker B and LID motifs in ATP binding proteins.
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Effect of FKBP12 in the Conformational Dynamics of RyR1
Tyler W.E. Steele, Edgar Leal-Pinto, Pablo Castro-Hartmann,
Montserrat Samso.
VCU School of Medicine, Richmond, VA, USA.
The ryanodine receptor (RyR) is an intracellular ion channel with an important
role in depolarization-induced Ca2þ release in excitable cells. For the skeletal
muscle isoform RyR1, the open and closed conformations were determined at
10 A˚ resolution by cryoEM, and their structural analysis suggest that RyR1,
with four inner helices forming a helical bundle, has a similar gating mechanism
to that of Kþ channels. Upon gating, RyR1’s large cytoplasmic domain also un-
dergoes conformational changes, underlying a long-range communication path-
way between the ion gate and effectors bound more than 130 A˚ away. One of
such effectors is the FK506-binding protein of 12 kDa (FKBP12), which we lo-
calized at the interface of the ‘‘handle’’ and the ‘‘clamp’’ domains of RyR1. At
the functional level, and under activating [Ca2þ] concentrations, single channel
experiments with purifiedRyR1 show that FKBP12 increasedRyR1’s Po and re-
distributed its subconductance states towards higher conductance levels. At the
structural level, we found that under sub-activating [Ca2þ] concentrations and in
the absence of FKBP12, RyR1’s cytoplasmic domain appears to be a structural
intermediate of the well-defined open- and closed-state RyR1-FKBP12 confor-
mations, whereas the inner helices remain in the closed conformation. Overall,
our studies suggest that while [Ca2þ] exerts a dominant effect in RyR1’s gating,
FKBP12 changes the energy landscape of RyR1’s structural transitions.
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Stabilization of the Skeletal Muscle Ryanodine Receptor Ion Channel-
FKBP12 Complex by the 1,4-Benzothiazepine Derivative S107
Yingwu Mei1, Le Xu1, Henning H. Kramer2, Ginger H. Tomberlin2,
Claire Townsend2, Gerhard Meissner1.
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Activation of the skeletal muscle ryanodine receptor (RyR1) complex results in
the rapid release of Ca2þ from the sarcoplasmic reticulum and muscle contrac-
tion. Dissociation of the small FK506-binding protein 12 subunit (FKBP12) in-
creases RyR1 activity and leads to the impairment of muscle function. The 1,4-
benzothiazepine derivative JTV519, and more specific derivative S107
(2,3,4,5,-tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine), are thought to
improve skeletal muscle function by stabilizing the RyR1-FKBP12 complex.
Here, we report that SR vesicles enriched in RyR1 bound a large number of
S107 molecules with micromolar affinity. The effects of S107 and FKBP12
on RyR1 were examined under conditions that altered the redox state of
RyR1. In SR vesicles, S107 increased FKBP12 binding to RyR1 in presence
of reduced glutathione and the NO-donor NOC12. S107 was without effect
in the presence of oxidized glutathione. Addition of 0.15 mM FKBP12 to SR
vesicles prevented FKBP12 dissociation, whereas in the presence of oxidized
glutathione and NOC12 FKBP12 dissociation was observed in skeletal muscle
homogenates that contained 0.43 mM myoplasmic FKBP12, and this dissocia-
tion was attenuated by S107. In single channel measurements, pretreatment of
FKBP12-depleted RyR1s with S107 in the absence and presence of NOC12
augmented the FKBP12-mediated decrease in channel activity. The data sug-
gest that S107 can reverse the harmful effects of redox active species on SR
Ca2þ release in skeletal muscle.
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Investigating the Relationship between FKBP Structure and the Ability to
Activate RyR Channels
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We have recently demonstrated, both at the single-channel level and in iso-
lated cardiac cells (Galfre et al., (2011) PLoS ONE, 7, Issue 2, e31956), that
the cardiac RyR (RyR2) is activated by FKBP12 and that this effect is reg-
ulated by the antagonistic action of FKBP12.6. We now investigate whether
FKBPs can also activate skeletal RyR (RyR1) and examined the relationshipbetween FKBP structure and the ability to activate RyR1 and RyR2. We
generated a mutant FKBP12 (FKBP12E31Q/D32N/W59F) where the amino acids
Glu31, Asp32 and Trp59 were mutated to the respective residues found in
FKBP12.6 (Gln, Asn and Phe). The effects of the wild type and mutant
FKBP12E31Q/D32N/W59F proteins on the single-channel gating of RyR1 and
RyR2 were then compared. Our results show that FKBP12.6 promotes acti-
vation of RyR1 whereas FKBP12 promotes activation of RyR2. The FKBP12
mutant, FKBP12E31Q/D32N/W59F did not alter RyR2 Po (n=5) but caused sig-
nificant activation of RyR1; for example Po was 0.02150.008 before and
0.11050.026 after addition of cytosolic 1 mM FKBP12E31Q/D32N/W59F
(SEM; n=7; **p<0.01)). The FKBP12 mutant, therefore, no longer behaves
like FKBP12 but instead mimics the actions of FKBP12.6 on both RyR iso-
forms. In conclusion, we demonstrate that FKBP12 and FKBP12.6 specifi-
cally activate RyR2 and RyR1, respectively. Our results also suggest that
the ability of FKBP12 and FKBP12.6 to activate RyR channels is contained
within just three amino acid residues of FKBP12 (Glu31, Asp32 and Trp59)
and the corresponding residues in FKBP12.6 (Gln31, Asn32 and Phe59). These
results shed new light on the interactions of FKBPs with RyR channels and
will be important for understanding the dual role of FKBP12 and FKBP12.6
as regulators of sarcoplasmic reticulum Ca2þ-release in cardiac and skeletal
muscle.
Supported by the BHF
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FRET-based Mapping of Regions involved in FKBP12.6 Binding to the
Type 1 Ryanodine Receptor
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The type 1 ryanodine receptor (RyR1) is an intracellular calcium channel that
plays an integral role in skeletal muscle excitation-contraction coupling. The
functional properties of this protein are regulated by numerous associated pro-
teins, including FKBP12, a skeletal muscle protein that stabilizes full RyR1
channel gating. While the binding site of FKBP12 was originally identified at
position 2458 of RyR1, subsequent reports have localized additional binding
determinants within the N-terminal domain of RyR1. In this study, we used
fluorescence resonance energy transfer (FRET) to determine the orientation
and proximity of FKBP relative to sites either within the N-terminal domain
or near amino acid position 2458. We utilized the cardiac muscle isoform
FKBP12.6 (which binds to RyR1 at the same site as FKBP12 but with higher
affinity and stability) labeled with the FRET donor Alexa Fluor 488 at either
position 14, 44, 49, or 85. Specific binding of each labeled FKBP to RyR was
confirmed in permeabilized HEK-293T cells expressing wtRyR1. Weak energy
transfer was observed from FKBP12.6 to the FRET acceptor Cy3NTA, which
was targeted to poly-histidine ‘‘tags’’ placed in the N-terminal domain. This re-
sult suggested that the acceptors were not proximal (~90A˚ away) to FKBP12.6
bound to RyR1. Next, we measured FRET from FKBP12.6 to Cy3NTA targeted
to positions 2157, 2341, 2502 and 2777 of RyR1. FKBP12.6 binding to con-
structs containing His-tags at positions 2157 and 2502 was significantly reduced
relative to binding to wtRyR1. In contrast, we detected strong and weak FRET
efficiencies from FKBP12.6 to positions 2341 and 2777, respectively. These
data suggest that FKBP12.6 binds near amino acid position 2341 but far from
the N-terminal domain of RyR1. Supported by NIH grant R01AR059124 (to
JDF and TG) and R01HL092097 (to RLC).
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Physiological Role(S) of RyR1 in Smooth Muscle Cells
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Type 1 ryanodine receptor (RyR1) is a key protein involved in the regulation of
the intracellular Ca2þ concentration in skeletal muscle cells, playing a crucial
role in muscle contraction by releasing Ca2þ from the sarcoplasmic reticulum
after plasma membrane depolarization. Dysregulation of calcium signals due to
defects in RyR1 have been associated with a wide range of primary neuromus-
cular disorders, including Malignant Hyperthermia Susceptibility and a number
of congenital myopathies including Core Myopathies, some forms of Centronu-
clear myopathy and congenital fiber type disproportion. Though RyR1 is pref-
erentially expressed in skeletal muscles recent data has shown that it is also
expressed in some areas of the central nervous system, in some cells of the im-
mune system (B-lymphocytes and dendritic cells) and in smooth muscle cells.
Thus mutations in RYR1 (the gene encoding RyR1) may lead to alterations of
Ca2þ homeostasis not only in skeletal muscle, but also in other tissues express-
ing this intracellular calcium release channel.
